id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-P-1641-0009,FDA,FDA-2013-P-1641,"Citizen Petition Denial Response from FDA CDER to Teva Neuroscience, Inc.",Other,Denial,2014-05-05T04:00:00Z,2014,5,2014-05-05T04:00:00Z,,2014-05-05T18:45:40Z,,0,0,09000064816e2a7e
FDA-2013-P-1641-0006,FDA,FDA-2013-P-1641,Supplement from Teva Pharmaceutical Industries Ltd.,Other,Supplement (SUP),2014-03-26T04:00:00Z,2014,3,2014-03-26T04:00:00Z,,2014-03-26T21:04:25Z,,0,0,0900006481683ff7
FDA-2013-P-1641-0005,FDA,FDA-2013-P-1641,"Memorandum of Meeting Minutes February 25, 2014",Other,Minutes,2014-03-12T04:00:00Z,2014,3,2014-03-12T04:00:00Z,,2014-03-12T16:13:13Z,,0,0,0900006481661939
FDA-2013-P-1641-0004,FDA,FDA-2013-P-1641,"Presentation from TEVA Pharmacuetical  re February 25, 2014 Type C FDA Meeting on Scientific Data on Copaxone’s Complexity and Mode of Action in Consideration of Evidentiary Standards for Follow on Products",Other,Presentation,2014-03-05T05:00:00Z,2014,3,2014-03-05T05:00:00Z,,2014-03-06T14:40:23Z,,0,0,09000064815fccf0
FDA-2013-P-1641-0003,FDA,FDA-2013-P-1641,Supplement from TEVA Pharmaceutical Industries Ltd.,Other,Supplement (SUP),2014-02-04T05:00:00Z,2014,2,2014-02-04T05:00:00Z,,2014-03-05T20:18:54Z,,0,0,0900006481535e8e
FDA-2013-P-1641-0002,FDA,FDA-2013-P-1641,Acknowledgement Letter to TEVA Pharmaceuticals,Other,Acknowledgement Letter/Receipt,2013-12-23T05:00:00Z,2013,12,2013-12-12T05:00:00Z,,2013-12-23T15:14:12Z,,0,0,09000064814c457d
FDA-2013-P-1641-0001,FDA,FDA-2013-P-1641,Citizen Petition from TEVA Pharmaceuticals,Other,Citizen Petition,2013-12-12T05:00:00Z,2013,12,2013-12-12T05:00:00Z,,2024-11-07T22:59:42Z,,1,0,09000064814c4529